Does Medicare Cover Cancerguard? Costs and 2028 Pathway

Medicare does not cover Cancerguard. The multi-cancer early detection blood test from Exact Sciences is sold only as a self-pay product at $689, is not billed to any insurance, and has not been approved by the FDA, which is a prerequisite for Medicare coverage.¹ A federal law signed in February 2026 sets up a coverage pathway for FDA-approved multi-cancer detection tests beginning January 1, 2028, so Cancerguard could become eligible later if it clears the FDA.²

Why Medicare Won’t Pay for It

Cancerguard is a laboratory-developed test that screens for signals of more than 50 cancer types from a single blood draw, analyzing DNA methylation patterns and protein biomarkers.³ It is performed by Exact Sciences Laboratories under CLIA certification and CAP accreditation. That regulatory status lets the company sell the test, but it does not make the test eligible for Medicare reimbursement.¹

The same is true of the competing Galleri test from GRAIL, which is likewise sold without FDA approval and is not covered by Medicare or most private insurers.⁴ No multi-cancer early detection test currently qualifies for Medicare coverage.

What You Pay Out of Pocket

The self-pay price is $689, and Exact Sciences does not bill insurance. The cost is eligible for payment through health savings accounts and flexible spending accounts.⁵ There is no separate charge for the blood draw when patients use the company’s managed phlebotomy network.⁶

The bigger financial exposure sits behind the test, not on it. A positive Cancerguard result triggers recommended follow-up imaging such as contrast-enhanced CT or PET-CT, which can run into the thousands of dollars. Insurers may decline to pay for those scans because the test that prompted them is not an established standard of care.⁷ To cushion that risk, Exact Sciences runs an imaging reimbursement program that may cover up to $6,000 in non-covered follow-up imaging for eligible patients who test positive.¹

The 2028 Coverage Pathway

On February 3, 2026, President Trump signed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act into law as part of the Consolidated Appropriations Act, 2026. The measure had cleared the House on January 22, 2026 by a bipartisan vote of 341 to 88.⁸ It sets up a framework for Medicare to cover multi-cancer early detection tests once they receive FDA approval and demonstrate clinical benefit.²

The main terms:

Coverage for FDA-approved MCED tests begins January 1, 2028.
In 2028, coverage runs up to age 68, and the age ceiling rises by one year each following year.⁹
No more than one covered test every 11 months per beneficiary.¹⁰
Payment rates are set at parity with multi-target stool DNA tests such as Cologuard through 2030, after which CMS may adjust rates using the clinical laboratory payment system.²
Beneficiaries owe 20 percent coinsurance, consistent with Medicare’s rules for clinical diagnostic laboratory tests. If the U.S. Preventive Services Task Force later gives a specific test an “A” or “B” recommendation, that cost-sharing and the age limit fall away and the test moves under Medicare’s standard preventive-services rules.⁹

The law does not displace existing screenings. Coverage for mammograms, colonoscopies, lung cancer CT scans, and other standard tests continues unchanged.²

What Cancerguard Still Needs

For Cancerguard to fall under the new benefit, Exact Sciences must obtain FDA premarket approval. As of mid-2026, no multi-cancer detection test has received that approval.¹⁰ The FDA has granted Cancerguard an investigational device exemption for use in a real-world evidence registry, which is a research designation rather than an approval.¹¹ Exact Sciences has not publicly announced when it will file a formal premarket approval application.¹

GRAIL’s Galleri is further along. GRAIL submitted its final premarket approval application module to the FDA in January 2026, and as of June 2026 the agency was evaluating the submission.¹²¹³ Guardant Health’s Shield multi-cancer detection test, which is distinct from the company’s already FDA-approved Shield colorectal screening test, received FDA Breakthrough Device designation in June 2025 with a prospective study underway.¹⁴

Blood-Based Cancer Screenings Medicare Does Cover

Multi-cancer detection tests are the gap. Some single-cancer blood tests are already covered under Medicare Part B:

An FDA-approved blood-based biomarker test for colorectal cancer screening is covered once every three years for average-risk beneficiaries aged 45 to 85 with no symptoms of colorectal disease. Guardant Health’s Shield, approved in 2024, is the test that currently qualifies. Fee-for-service beneficiaries pay nothing when the provider accepts assignment.¹⁵¹⁶¹⁷
The prostate-specific antigen (PSA) blood test is covered once every 12 months for men over 50, at no cost when the provider accepts assignment.¹⁸

Most preventive screenings under Part B carry no cost-sharing when the provider accepts assignment, a rule set by the Affordable Care Act.¹⁹ Diagnostic tests ordered because of symptoms or abnormal findings are treated differently and are subject to the Part B deductible and 20 percent coinsurance.²⁰

If you decide to pay for Cancerguard on your own, you will need a physician’s order and can budget the $689 as an HSA or FSA expense. Just plan for the possibility of uncovered follow-up imaging if the result comes back positive, and check whether the Exact Sciences imaging reimbursement program applies to your situation before you draw blood.

1
Exact Sciences. Cancerguard MCED Providers Resources
2
Millermeeks.house.gov. Miller-Meeks Bill to Detect and Prevent Cancer Signed Into Law
3
Exact Sciences. Cancerguard MCED for Providers
4
American Cancer Society. Multi-Cancer Early Detection Tests
5
Cancerguard. Request the Cancerguard Test
6
Cancerguard. Cancerguard FAQ
7
StraightHealthcare. Cancerguard Test
8
Sewell.house.gov. Rep. Sewell Celebrates House Passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
9
GovInfo. Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act Committee Report
10
AZBio. Long-Awaited Legislation on Multi-Cancer Early Detection Tests for Medicare Beneficiaries Becomes Law
11
National Library of Medicine. Multi-Cancer Screening Tests
12
NPR. Blood Test Multi-Cancer Early Detection MCED
13
GRAIL. GRAIL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test
14
Guardant Health. FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection Test
15
Medicare.gov. Blood-Based Biomarker Tests for Colorectal Cancer Screening
16
Value-Based Cancer Care. Blood Test for Colorectal Cancer Obtains Approval
17
Shield Cancer Screen. Shield Coverage and Support
18
Medicare.gov. Your Guide to Medicare Preventive Services
19
Center for Medicare Advocacy. Making Sense of Medicare’s Preventive Service Benefits
20
Wellcare. Does Medicare Cover Cancer Treatment